Fate Therapeutics INC

Fate Therapeutics' stockholders approved an amendment to the 2022 Stock Option and Incentive Plan, increasing available shares by 7 million, and ratified the appointment of Ernst & Young LLP.

Fate Therapeutics released an updated corporate presentation detailing clinical progress in its off-the-shelf CAR T-cell therapy pipeline for autoimmune diseases and cancer.

Fate Therapeutics announced first quarter 2026 financial results, highlighting an extended operating runway into 2028 due to a 20% reduction in operating expenses.

Fate Therapeutics announced its Q4 and full year 2025 financial results, highlighting significant clinical advancements in off-the-shelf CAR T-cell therapies and a strong cash runway.

Fate Therapeutics reports Q3 2025 financial results, highlighting clinical advancements in autoimmune and oncology programs and a projected operating runway through year-end 2027.

Fate Therapeutics announced promising Phase 1 clinical data for its off-the-shelf CAR T-cell therapy, FT819, in patients with moderate-to-severe systemic lupus erythematosus, demonstrating immune remodeling and durable responses.

Fate Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing financial results, ongoing clinical development, and risk factors.

Fate Therapeutics reported reduced net losses and operating expenses in its latest quarterly filing, driven by strategic restructuring and ongoing clinical development of its iPSC-derived cell immunotherapies.

Fate Therapeutics announced a reduced net loss for Q2 2025, driven by decreased operating expenses, despite a significant decline in collaboration revenue and a 12% workforce reduction.

Fate Therapeutics announces its Q1 2025 financial results, showing a net loss of $37.6 million and provides updates on its clinical development programs.

Fate Therapeutics' third quarter 2024 report details ongoing clinical trials, financial results, and a collaboration amendment with Ono Pharmaceutical.

Fate Therapeutics reports a net loss of $86.4 million for the first half of 2024, while highlighting advancements in its iPSC-derived cell therapy programs.

Fate Therapeutics, a clinical-stage biopharmaceutical company, reported reduced net losses in 2025 while advancing its iPSC-derived cellular immunotherapy pipeline for autoimmune diseases and cancer.

Fate Therapeutics' 10-K filing highlights advancements in its iPSC-derived cell therapy pipeline, particularly in autoimmune diseases and solid tumors, with ongoing clinical trials and strategic partnerships.

Fate Therapeutics and Ono Pharmaceutical Co., Ltd. have amended their collaboration agreement, increasing the estimated annual collaboration budget for research and development.

Redmile Group, LLC reported the acquisition of 87,900 stock options in Fate Therapeutics, Inc. as compensation for board service.

Director Michael Lee was granted 87,900 stock options in Fate Therapeutics, which are held for the benefit of Redmile Group.

Yuan Xu, a Director at Fate Therapeutics, received a grant of stock options.

Director Karin Jooss of Fate Therapeutics was granted stock options as part of the company's director compensation policy.

Robert S. Epstein, a Director at Fate Therapeutics, Inc., received a grant of stock options.

Shefali Agarwal, a Director at Fate Therapeutics, received a grant of stock options as part of the company's annual equity awards for non-employee directors.

Fate Therapeutics' 2026 proxy statement outlines director elections, auditor ratification, executive compensation, and a proposal to increase the 2022 Stock Option and Incentive Plan share reserve by 7 million shares.

Fate Therapeutics will hold its annual stockholders meeting on May 29, 2025, to vote on director elections, auditor ratification, executive compensation, and amendments to the company's charter and stock option plan.

Fate Therapeutics is holding its 2025 Annual Meeting of Stockholders to vote on key proposals, including increasing authorized common stock and amending the 2022 Stock Option and Incentive Plan.

Fate Therapeutics announces its Annual Meeting of Stockholders to be held on June 7, 2024, outlining proposals including director elections, auditor ratification, executive compensation approval, officer exculpation, and stock plan amendment.

Fate Therapeutics is holding its annual meeting to vote on key proposals including director elections, auditor ratification, executive compensation, officer exculpation, and an amendment to the stock option and incentive plan.

Redmile Group, LLC has completed an internal reorganization of its holdings in Fate Therapeutics, shifting assets to specialized subsidiaries while maintaining a 14.9% aggregate stake.

Redmile Group, LLC, a key investor in Fate Therapeutics Inc., has elected to increase its maximum beneficial ownership percentage of pre-funded warrants from 9.99% to 14.99%, effective 61 days after July 1, 2025.

The Vanguard Group reports zero beneficial ownership in Fate Therapeutics Inc. following an internal realignment.

Schonfeld Strategic Advisors LLC has filed an amended Schedule 13G, disclosing a 0.82% beneficial ownership stake in Fate Therapeutics, Inc. as of June 30, 2025.

Goldman Sachs Group and Goldman Sachs & Co. LLC report beneficial ownership of 2.0% of Fate Therapeutics' common stock as of June 30, 2025.

The Vanguard Group has disclosed a 7.64% passive ownership stake in Fate Therapeutics Inc., holding 8,766,764 shares of common stock.

Schonfeld Strategic Advisors LLC has reported a significant beneficial ownership stake of 6.80% in Fate Therapeutics, Inc., holding 7,794,513 shares of common stock as of March 31, 2025.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have disclosed a passive beneficial ownership of 7.4% in Fate Therapeutics, Inc. common stock.